Visiongain has launched a new report Dermatological Drugs Market Report 2021-2031: Forecasts by Disease (Psoriasis, Dermatitis, Acne, Skin Infections, Other Diseases), by Skin Infections Drugs (Bepanthen/Bepanthol, Protopic, Dermovate), by Psoriasis Drugs (Humira, Stelara, Enbrel, Remicade, Taltz, Otezla), by Dermatitis Drugs (Cubicin, Zyvox, Valtrex, Canesten, Lamisil, Other Dermatitis Drugs), by Route of Administration (Topical, Oral, Parenteral Administration) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Dermatological Drugs Companies AND COVID-19 Recovery Scenarios.

Which Key Players Are Leading the Global Market and how much share do they Hold?
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as:
• Mergers and acquisitions.
• Product launches.
• Collaborations and partnerships.

Product approval is a major milestone facing all key competitors in the dermatological drugs market. Several strategies were implemented by key market players between 2015 and Jan 2021.

Discover sales predictions for the global dermatological drugs market and submarkets
Along with revenue prediction for the overall world market, there are 5 segmentations of the dermatological drugs market, with forecasts for 5 disease type, 3 Skin Infections, 6 Psoriasis Drugs, 4 Products each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

Leading companies and the potential for market growth
As per Visiongain analysis, global dermatological drugs market is estimated to be valued at US$xxlion in 2021 and is projected to reach at a market value of US$xx billion by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Why You Should Buy Visiongain Report only?
The report study aims to explore the market drivers, restraints and also market opportunities facing dermatological drugs product stakeholders in different geographic areas. Also, it identifies trends, gaps, and opportunities in each micro market segment. Finally, this report identifies the major stakeholders, product portfolios, and recent developments in order to draw a competitive landscape for players in this market.

Leading Players in the Market
• AbbVie Inc. (AbbVie)
• Abbott Laboratories
• Bayer Pharmaceuticals
• Bristol-Myers Squibb
• Cadila Healthcare
• Cipla
• Dr Reddy’s
• GlaxoSmithKline
• Glenmark Pharmaceuticals Limited
• L’Oreal SA
• Lupin Limited
• Pfizer Inc. (Pfizer)
• Merck Group Chemicals
• Sun Pharma
• Taro Pharmaceutical Industries Ltd
• Johnson & Johnson Inc.
• Roche Holding AG (Roche)
• Sun Pharmaceutical Industries Limited
• Sanofi Pasteur Pharmaceutical
• Takeda Pharmaceutical Company Limited
• Taro Pharmaceutical Industries Ltd. (Taro)

Key Questions Answered by this Report:
• What is the current size of the overall global microbiome therapeutics market? How much will this market be worth from 2021 to 2031?
• What are the main drivers and restraints that will shape the overall dermatological drugs market over the next ten years?
• What are the main segments within the overall dermatological drugs market?
• How much will each of these segments be worth for the period 2021 to 2031?
• How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for the world dermatological drugs?
• What is their current status and how will they develop over the next ten years?
• What are their revenue potentials to 2031?
• How will political and regulatory forces influence regional markets?
• How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are the leading dermatological drugs? What are their revenues and latest developments?
• What are some of the most prominent human dermatological drugs currently in development?
• What are the main trends that will affect the world dermatological drugs market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that industry over the next ten years?
• How will the global dermatological drugs market evolve over the forecasted period, 2021 to 2031?
• Which drugs can succeed and what revenues could they generate to 2031?
• What will be the main commercial drivers for the market from 2021 to 2031?
• How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
• How will that industry evolve between 2021 and 2031, especially in R&D?

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.